CRH, the principal regulator of the hypothalamic-pituitary-adrenal axis and modulator of autonomic nervous system activity, also participates in the regulation of appetite and energy expenditure. Antalarmin, a pyrrolopyrimidine compound, antagonizes CRH type 1 receptor-mediated effects of CRH, including pituitary ACTH release, stress behaviors, and acute inflammation. We administered antalarmin chronically to evaluate its effects on hypothalamic-pituitaryadrenal axis function and metabolic status. Adult male rats were treated twice daily with 20 mg/kg of ip antalarmin or placebo over 11 days. The animals were weighed; plasma ACTH, corticosterone, leptin, and blood glucose levels were determined; and morphometric analyses were performed to determine adrenal size and structure, including sizing, histochemistry, immunohistochemistry, and electron microscopy. Leptin messenger RNA expression in peripheral fat was analyzed by Northern blot. Antalarmin decreased plasma ACTH (mean Ϯ SD, 2.62 Ϯ 0.063 pg/ml) and corticosterone concentrations (10.21 Ϯ 1.80 g/dl) compared with those in vehicle-treated rats [respectively, 5.3 Ϯ 2.0 (P Ͻ 0.05) and 57.02 Ϯ 8.86 (P Ͻ 0.01)]. Antalarmin had no significant effect on body weight, plasma leptin, or blood glucose concentrations or fat cell leptin messenger RNA levels. The width of the adrenal cortex of animals treated with antalarmin was reduced by 31% compared with that in controls without atrophy of the gland. On the ultrastructural level, adrenocortical cells were in a hypofunctional state characterized by reduced vascularization, increased content of lipid droplets, and tubulovesicular mitochondria with fewer inner membranes. The apoptotic rate was increased in the outer zona fasciculata of animals treated with the antagonist (26.6 Ϯ 3.58%) compared with that in placebo-treated controls (6.8 Ϯ 0.91%).
T HERE is a well established relation between the activity of the hypothalamic-pituitary-adrenal (HPA) axis and the nutritional status of mammals. CRH is the principal regulator of the HPA axis and, consequently, adrenal glucocorticoid production (1) . Central administration of CRH inhibits feeding and reduces body weight, whereas starvation is associated with activation of the HPA axis (2) (3) (4) (5) . Leptin, a newly discovered hormone secreted by adipocytes, decreases food intake and body weight in obese and lean animals and increases energy expenditure (4, 6) . Plasma leptin concentrations correlate tightly with the body mass index or other indexes of adiposity, and there is a reciprocal relation between leptin and the activity of the HPA axis (7, 8) . Leptin inhibits hypothalamic CRH secretion (9 -11) and directly blocks glucocorticoid production at the level of the adrenal gland (12) . On the other hand, glucocorticoids acutely induce the expression of leptin messenger RNA (mRNA) in fat tissue and increase circulating leptin levels, whereas chronically they cause elevations of leptin concentrations as a result of increased body adiposity (13) (14) (15) (16) .
The nonpeptide CRH antagonist 154,526 and a close analog, antalarmin, have a high affinity for the CRH type 1 receptor and in acute rat studies block CRH-stimulated ACTH release and carrageenan-induced inflammation and produce anxiolysis (17) (18) (19) (20) . The existence of redundant hypophysiotropic factors for ACTH release, such as arginine vasopressin (AVP) and norepinephrine, and the finding that a CRH gene knockout mouse does not have complete deficiency of HPA function (21) , raises the possibility that chronic administration of a CRH antagonist may be met with escape and normalization of ACTH and cortisol release, due to increased release of alternate ACTH secretagogues from the hypothalamus. In addition, the known relations between the HPA axis and the regulation of food intake and energy expenditure generate questions as to the potential effects of a chronically administered CRH antagonist on the body weight and metabolic status of an individual. Thus, data on the chronic effects of a CRH antagonist are quite critical in predicting the clinical utility of such an agent. We designed an 11-day study to analyze the chronic effects of antalarmin on pituitary-adrenal function and maintenance of body weight and metabolic status. [2,5,6-trimethyl-7-(2,4,6- 
Materials and Methods

Synthesis of antalarmin
amine was synthesized in five steps from 2,4,6-trimethylaniline, using modifications of the procedure reported by Chen (International Patent WO 94/13676, June 23, 1994) . The pyrrolopyrimidine was purified by distillation (boiling point, 185-190 C/0.1 mm) and crystalization from methanol at 10 -15 C by the slow addition of water to a final concentration of 25% water in methanol (melting point, 81-82 C). Nuclear magnetic resonance (300 megahertz, CDCl3, Varian XL-300, Palo Alto, CA) gave identical peaks to the published values. CIMS (Finnigan 1015 mass spectrometer, Sunnyvale, CA) gave the required Mϩ1 peak, and C, H, N combustion analysis (Atlantic Microlabs, Atlanta, GA) was within Ϯ0.4% of calculated values. Product homogeneity was confirmed by TLC analysis (Analtech Uniplate silica gel GHLF, Newark, DE).
Animal procedure
Adult male Sprague-Dawley rats were purchased from Taconic Farms (Germantown, NY) and were housed three per cage under controlled environmental conditions. Rats were exposed to a standard 14-h light, 10-h dark cycle, and feed and water were supplied ad libitum. Animals were given ip injections of either vehicle alone or 20 mg/kg antalarmin twice daily at approximately 10-to 12-h intervals for 11 days. They were weighed once per day in the morning. On the 11th day they FIG. 1. A, Mean Ϯ SEM weight changes in rats treated with a CRH antagonist (antalarmin; n ϭ 4) or vehicle (n ϭ 4) over 11 days. Mean blood glucose levels (B), plasma leptin levels (C), and ob mRNA expression (D) after 11 days of treatment are shown.
were decapitated, and trunk blood was collected into EDTA-containing tubes on ice for hormone determinations. The decapitation procedure was performed sequentially in a separate room, and each animal was killed within 3 min of being removed from its home cage. Abdominal fat and adrenal tissues were rapidly dissected and either frozen on dry ice and stored at Ϫ70 C or stored in fixative as described below.
A dose of 20 mg/kg was chosen for the chronic studies, as this quantity was previously shown to block the biological effects of CRH on ACTH secretion and carrageenan-induced sc inflammation (18) .
General histology and morphometric analysis
Adrenal tissue was fixed in 4% formalin solution, paraffin embedded and sectioned, then mounted on slides and deparaffinized.
For histology, the slides were stained with hematoxylin-eosin. Sections were cut from the largest diameter of the gland, and the average width of the cortex was determined in each gland (n ϭ 4), with an average of at least six different sections from each adrenal. 
Electron microscopy
In situ end labeling
Detection of apoptosis on tissue sections was performed with the terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick end-labeling (TUNEL) assay. This technique enables identification of individual cells undergoing apoptosis in tissue sections with heterogeneous cell populations.
The In Situ Cell Death Detection kit, POD (Boehringer Mannheim, Indianapolis, IN), was used according to the instructions of the manufacturer. Briefly, after deparaffinization and rehydration, the tissue sections were treated with 20 g/ml proteinase K (Life Technologies, Gaithersburg, MD) at 37 C for 30 min. Endogenous peroxidase activity was quenched in methanol containing 0.5% H 2 O 2 for 30 min. The slides were then washed twice with PBS and incubated with the TUNEL reaction mixture (TdT with fluorescein-labeled nucleotides in TdT buffer) at 37 C for 1 h. Subsequently, they were washed three times with PBS and incubated with Converter-POD (POD-conjugated antifluorescein antibody) at room temperature for 30 min. Diaminobenzidine was used to visualize the apoptotic nuclei. Heavily stained, dark brown nuclei were considered apoptotic.
Quantification of apoptotic rate
The number of positively stained nuclei was analyzed in representative quadrangular areas of identical size within the zona fasciculata of the adrenal cortex. In each section, positive steroid cells per total number of cells were obtained by counting 100 cells; areas of necrosis were excluded. The results for each group are given as the percent mean Ϯ sem of four different areas in four animals in each group.
RNA isolation and Northern blot
Fat was dissected and immediately frozen in liquid nitrogen. The samples were homogenized with a Polytron homogenizer (Brinkmann Instruments, Westbury, NY) in 4 mol/liter guanidine thiocyanate supplemented with 7% mercaptoethanol. Lysates were layered on a cesium chloride cushion (5.88 mol/liter) and centrifuged at 28,000 rpm (rotor SW40) at 20 C for 29 h. Pelleted RNA was dissolved on 300 l sodium acetate-Tris buffer and neutralized by the addition of 50 l 2 mol/liter potassium acetate (pH 5.5). Samples of total RNA were separated by electrophoresis on 1% agarose gels containing formaldehyde and transferred onto nylon membranes (Hybond N ϩ , Amersham-Buchler, Braunschweig, Germany). Before transfer, gels were stained with ethidium bromide to ascertain that equal amounts of total RNA had been separated. Probes were generated with the Klenow fragment of DNA polymerase I and [␣-
32 P]deoxy-CTP from the partial ob complementary DNA, as previously described (22), by random oligonucleotide priming. The nylon membranes were hybridized at 42 C, and blots were washed once with 0.8 ϫ SCC (standard saline citrate)-1% SDS for 10 min at 55 C. Autoradiographs were analyzed with the LKB laser densitometer and the software GelScan 2.0 from Pharmacia (Piscataway, NJ).
Hormone measurements
For all measurements, blood was taken after decapitation of the animals into a chilled vial with EDTA and immediately centrifuged at 1600 ϫ g at 4 C for 15 min. Plasma was stored at Ϫ70 C until analysis. Leptin was measured by a commercially available RIA (Linco Research, St. Charles, MO). Controls were used in the low and high sections of the standard curve. Samples were used in duplicate, and standards were used in triplicate. The intra-and interassay coefficients of variation were both below 5%. ACTH and corticosterone were measured by RIAs (Brahms Diagnostica, Berlin, Germany). The intra-and interassay variations were less than 8%.
Statistical analysis
Data analyses were performed on an IBM-compatible computer using SigmaPlot (Jandel Scientific, Chicago, IL) and Statistica (StatSoft, Tulsa, OK). Differences in plasma ACTH, corticosterone, glucose, and leptin FIG. 2. Mean Ϯ SEM plasma ACTH and corticosterone were significantly reduced (*, P Ͻ 0.05; **, P Ͻ 0.01) in rats treated with antalarmin (n ϭ 4) or vehicle (n ϭ 4). levels were assessed by unpaired Student's t test. Data are expressed as the mean Ϯ sem.
Results
Body weight and metabolic status
Chronic treatment with antalarmin did not induce any major changes in body weight or metabolic status. The initial mean weight in the treated group was 420 Ϯ 7.9 vs. 406 Ϯ 9.0 g in controls. After 11 days of treatment with antalarmin, mean weight was 429 Ϯ 8.9 vs. 414 Ϯ 9.9 g (Fig. 1a) . Mean morning blood glucose levels were not significantly different in the two groups (Fig. 1b) . Mean plasma leptin values were 3.4 Ϯ 1 pmol/liter in antalarmin-treated animals vs. 3.2 Ϯ 0.7 pmol/liter in controls (Fig. 1c) . Northern blot analysis demonstrated variable ob mRNA expression, with no significant differences between antalarmin-and vehicle-treated animals (Fig. 1d) .
Pituitary-adrenal status
After 11 days of treatment with antalarmin or vehicle, mean plasma ACTH and corticosterone levels were significantly lower [ACTH, 2.62 Ϯ 0.063 pg/ml (P Ͻ 0.05); corticosterone, 8.86 Ϯ 1.80 (P Ͻ 0.01)] in the antagonist than in vehicle-treated animals (respectively, 5.3 Ϯ 2.0 and 57.02 Ϯ 10.21; Fig. 2, a and b) . There was a mild decrease in the adrenocortical widths of antagonist-treated animals (0.95 Ϯ 0.09 mm) compared with those of vehicle-treated animals (1.38 Ϯ 0.10; P Ͻ 0.005; Fig. 3) .
On the ultrastructural level, adrenocortical cells were characterized by their typical tubulovesicular mitochondria. In vehicle-treated animals, there was a high number of large vesicular mitochondria with dense inner membranes and ample smooth endoplasmic reticulum (SER) in the cytoplasm. Adrenocortical cells formed filopodia (Fig. 4A) . In the antalarmin-treated animals, adrenocortical cells demonstrated an increased number of liposomes and fewer mitochondria with tubulovesicular inner membranes (Fig. 4B) . In vehicle-treated animals, subcapsular glomerulosa cells demonstrated characteristic oval or elongated tubulovesicular mitochondria, perinuclear Golgi apparatus, and filopodia (Fig. 5A ). In the antalarmin-treated animals, mitochondria were more rounded with vesicular inner membranes, demonstrating a fasciculata-type appearance (Fig. 5B) .
Determination of apoptosis on tissue sections performed with the TUNEL assay demonstrated a marked increase in heavily stained dark brown nuclei in the zona fasciculata of antalarmin-treated animals (26.6 Ϯ 3.58%) compared with that in vehicle-treated animals (6.8 Ϯ 0.906%; Fig. 6 ). Cell shrinkage and condensation of nuclei were observed, whereas mitochondrial structures were preserved during the early phase in antalarmin-treated animals (Fig. 7A ). Cells exhibited a blackened nucleus, cell blebbing, and formation of apoptotic bodies containing cell membranes during later stages (Fig. 7B) .
Discussion
Chronic treatment with antalarmin led to reductions in plasma ACTH and corticosterone concentrations compared with those in control animals given vehicle placebo. CRH and AVP are thought to be the major pituitary ACTH secretagogues; however, other hormones participate in the regulation of ACTH secretion as well (23) . CRH and AVP exert synergistic effects on ACTH release, although only CRH increases ACTH synthesis (24, 25) . A permissive role for CRH and a dynamic role for AVP have been postulated, based on rat studies with neutralizing CRH antisera (26) . Recent work has shown that a CRH gene knockout mouse has impaired HPA axis function (21) , and that CRH is necessary for a normal circadian adrenocortical rhythm and an intact adrenal structure (27) . In accordance with these findings, our data demonstrate that treatment with a CRH type 1 receptor antagonist is associated with sustained, albeit mild, blockade of HPA axis function in adult rats, and that alternative ACTH secretagogues can, to some extent, substitute for CRH. The size of the adrenal cortex was reduced; however, there was no atrophy of this structure, and low normal production of adrenal corticosterone was preserved.
Alteration of organelles in adrenocortical cells reflects the functional status of the steroid-producing cells (28) . Particularly, the SER and mitochondria reveal an astonishing capacity to adapt to the varying demands for steroidogenesis (29) . While hypophysectomy leads to a decrease in SER and inner mitochondrial membranes, reflecting the hypofunctional status of the cells, administration of CRH or stress induces an increase in SER, volume of mitochondria, and volume of the area covered by mitochondrial membranes in the zona fasciculata (29, 30) . Consistently, in the animals treated with the CRH antagonist, there was a reduction in SER and inner mitochondrial membranes, providing evidence for chronic understimulation of adrenocortical steroidogenic activity.
Programed cell death or apoptosis preserves adrenocortical tissue homeostasis, zonation, and remodeling (31) . Hypophysectomy-induced decreases in ACTH secretion lead to adrenal atrophy by increasing apoptosis of the adrenal cortex, whereas administration of ACTH restores the normal apoptotic rate (32) (33) (34) . This is in accordance with our findings suggesting that an increased apoptotic rate in the outer zona fasciculata resulted in a reduction of adrenocortical width in the animals treated with the CRH type 1 receptor antagonist.
Although hypophysectomy does not affect the structure of the zona glomerulosa (34), CRH antagonist-treated animals had less well differentiated glomerulosa cells with a fasciculata-type appearance, as previously described in adrenal autotransplants (35) . The expected inhibition of the central autonomic system by the CRH antagonist may be of relevance. Both the sympathoadrenal system and local medullary CRH participate in the regulation of adrenocortical steroidogenesis (35) (36) (37) (38) (39) (40) . Therefore, both central and local inhibition of adrenal CRH might contribute to the greater reduction of plasma corticosterone levels than what would be expected from the concurrent decrease in ACTH levels. This is further underscored by our previous finding that CRH reduced adrenocortical atrophy in the absence of pituitary ACTH (40) . Indeed, apoptotic cell death is more widespread when the adrenal cortex is disconnected from its innervation and interaction with the adrenal medulla (41), whereas neurally dependent compensatory adrenal growth after unilateral adrenalectomy has been demonstrated (42) .
Finally, there was a conspicuous reduction in the vascularization of the inner zona fasciculata and reticularis in animals treated with antalarmin compared with that in controls. It is of interest to note that CRH acts as a very potent vasodilator of the adrenal gland (43) . Hence, the antagonist may block the action of CRH released from the adrenal medulla in response to splanchnic nerve stimulation, preventing dilation of the adrenal vasculature (44 -46) . Therefore, the dual actions of CRH on the adrenal cortex, via inhibition of ACTH secretion and through the sympatho- adrenal system, may explain why chronic treatment with the CRH antagonist does not fully reproduce the effects of hypophysectomy or treatment with glucocorticoids.
There is a well established marked relation between the nutritional status of mammals and the activity of the HPA axis (47) (48) (49) . The striking findings that adrenalectomy can restore the sensitivity to centrally given insulin in obese Zucker (fa/fa) rats that have a defect in the leptin receptor and that there is a marked effect of adrenalectomy on the leptin dose-response curve for the reduction of food intake underscore the important interaction between the HPA axis and the leptin system (4). CRH might, therefore, inhibit feeding and reduce body weight by decreasing the activity of leptin (4).
However, chronic antalarmin administration induced no significant changes in body weight, leptin secretion, or leptin mRNA expression, whereas plasma corticosterone levels and adrenal size were reduced. Several explanations may account for these findings. First, the endocrine and metabolic effects may be mediated by different types of CRH receptors. Although CRH stimulates the pituitary-adrenal axis via type 1 CRH receptors (for review, see Ref. 50) , it has been postulated that the anorectic effect of CRH may be mediated via type 2 CRH receptors. Indeed, urocortin, a CRH-related neuropeptide that appears to be the natural CRH type 2 receptor ligand, had appetite-suppressing effects at doses that did not activate the HPA axis (51) . As antalarmin is a selective type 1 CRH receptor antagonist, our data support the concept that the anorectic effect of CRH might be exerted primarily via type 2 CRH receptors.
Chronic administration or excess endogenous glucocorticoids lead to weight gain (49, (52) (53) (54) . High doses of glucocorticoids acutely increase leptin concentrations in vitro and in vivo, whereas adrenalectomy can partially normalize or prevent weight gain and obesity (55, 56) . While antagonizing the effect of CRH, antalarmin may concurrently suppress its central anorectic effect. However, the simultaneous reduction of adrenal glucocorticoid production may counteract such suppression and its sequelae of weight gain and associated metabolic changes. Glucocorticoids are necessary for sustaining normal glucose concentrations by stimulating gluconeogenesis and causing insulin resistance. The animals were kept in an ad libitum feeding state, which would increase the threshold for glucocorticoid deficiency-induced hypoglycemia.
Finally, CRH is only one of a large family of catabolic systems that induce anorexia, increase thermogenesis, and promote weight loss (4). Thus, serotonin, urocortin, and the melanocortin ␣MSH (50, 51, 57, 58) or other as yet unknown factors may come into play when CRH is inhibited. Although leptin is a stress-related peptide and acts on the HPA axis at central and peripheral levels (7, 9, 10 -12, 59 ), CRH does not change the leptin system. In accordance with our data, administration of ovine CRH to patients with Cushing's syndrome before and 10 days after curative surgery resulted in no changes in plasma leptin levels when measured over a 2-h period after iv CRH administration, whereas the appropriately elevated baseline plasma leptin levels in these obese patients before and after surgery remained unchanged (60) .
In conclusion, chronic treatment with antalarmin was well tolerated and had a mild, but clear, suppressive effect on the activity of the pituitary-adrenal axis. ACTH and corticosterone levels were lower, and adrenal size was reduced due to increased apoptosis in the outer zona fasciculata. Antalarmin did not induce significant body weight or metabolic changes, a highly desired property for a clinically useful CRH antagonist.
